FDA May Well Need OTC Drug Funding, But Stakeholders Want Program Specifics
This article was originally published in The Rose Sheet
Executive Summary
The monograph program was "instituted, really, many, many decades ago. We've been trying to implement it since," said CDER Director Janet Woodcock at a recent FDA hearing. While FDA drug leadership was candid in laying out a general case for industry user fees, stakeholders seek detail on how the additional funds would be used, among other specifics.
You may also be interested in...
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
In an update on discussions with industry about potential user fees to support FDA's OTC monograph program, CDER officials say "industry and public would suffer" absent new fees.
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
During update on user fee discussions with industry to support FDA's OTC monograph program work, CDER officials say "industry and public would suffer" absent new fees.
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
During update on user fee discussions with industry to support FDA's OTC monograph program work, CDER officials say "industry and public would suffer" absent new fees.